Indications:
Promethazine Hydrochloride

Pharmacology:
Promethazine is a phenothiazine derivative that inhibits the brain's postsynaptic mesolimbic dopaminergic receptors. It has a significant -adrenergic blocking action and inhibits hypothalamus and hypophyseal hormone release. It competes with histamine for the H1-receptor; the antiemetic action may be due to the muscarinic blocking effect. It also lowers the amount of stimulation to the brainstem reticular system.

The gastrointestinal system absorbs promethazine effectively. Clinical effects are seen after 20 minutes of oral ingestion and typically last four to six hours, however they might last up to 12 hours. The liver metabolizes promethazine to a number of chemicals, the most common of which are promethazine sulfoxides and N-demethylpromethazine in the urine.

Dosage (breakdown or, not) :

Adult: 
No specific dosage recommendations.

Child: 
 They may be treated more conveniently by the elixir containing 5 mg/5 ml.

Administration:
As an antihistamine in allergy:
Children of 2-5 years: 5-15 mg
Children of 5-10 years: 10-25 mg
In the case where two doses in 24 hours are required, the lower dose stated should be given.
As a sedative:
Children of 2-5 years: 15-20 mg
Children of 5-10 years: 20-25 mg
Given as a single night-time dose

Interaction:
Alcohol should be avoided during medication therapy since Promethazine Hydrochloride may enhance the activity of any anticholinergic substance, tricyclic antidepressant, sedative, or hypnotic.

Phenergan may cause false-positive or false-negative findings in immunologic urine pregnancy tests.

Phenergan should be stopped at least 72 hours before starting skin testing with allergen extracts since it inhibits the cutaneous histamine response, resulting in false-negative findings.

Contraindication: 
Promethazine is not recommended for children under the age of two.
Intolerance to promethazine or any of the excipients.
Phenergan should not be administered in individuals who are in a coma or have CNS depression from any cause. It should not be administered to newborns or preterm babies.
Phenergan should be avoided in individuals who have taken monoamine oxidase inhibitors in the last 14 days.

Side Effects: 
Neuroleptic Malignant Syndrome (NMS); CV effects (e.g. bradycardia, tachycardia, transient HTN, hypotension; jaundice, blood dyscrasias, extrapyramidal effects; IV inj: Severe tissue injury (e.g. gangrene), pain and burning, paralysis, thrombophlebitis, severe spasm of distal vessels, necrosis. Sedation, Confusion, Disorientation, Blurred vision, Hallucinations, Dystonias, Catatonic states, Euphoria, Excitation, Impotence, Urinary retention Potentially Fatal: Resp depression and apnoea esp in childn.

Pregnancy: 
Although there is epidemiological evidence for the safety of promethazine in pregnancy and animal studies have indicated no risk, it should not be taken in pregnancy unless the doctor believes it is absolutely necessary. The use of Phenergan in the two weeks preceding birth is not advised due to the possibility of irritability and excitation in the neonate. Promethazine has produced long-term neurological problems in infants when administered in large dosages during late pregnancy. Promethazine should only be taken during pregnancy if the potential benefits to the patient outweigh the potential risks to the fetus. Breastmilk contains promethazine.There is a possibility of neonatal irritability and excitation.
Precautions & Warnings: 
The use of promethazine should be avoided in children and adolescents with signs and symptoms suggestive of Reye’s syndrome.
Promethazine may thicken or dry lung secretions and impair expectoration. It should therefore be used with caution in patients with asthma, bronchitis or bronchiectasis.
Use with care in patients with severe coronary artery disease.
Use with care in patients with narrow angle glaucoma.
Use with care in patients with epilepsy.
Use with care in patients with hepatic insufciency.
Use with care in patients with renal insufciency.
Caution should be exercised in patients with bladder neck obstruction.
Caution should be exercised in patients with pyloro-duodenal obstruction.

Storage Conditions:
Store at a cool and dry place. Protect from light.